Milrinon Devrimed (Milrinone)

Milrinone, the active ingredient in Milrinon Devrimed, is a phosphodiesterase‑3 inhibitor presented as an intravenous solution for intravenous use. It is employed in the management of acute decompensated heart failure and cardiogenic shock in hospitalized patients who require rapid hemodynamic support.

GNH USA supplies Milrinon Devrimed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Milrinone acts as an inotropic and vasodilator agent for severe cardiac conditions.

Acute decompensated heart failure: improves cardiac output and reduces systemic vascular resistance. Cardiogenic shock: provides essential inotropic support to maintain organ perfusion. Post‑cardiac surgery low cardiac output: assists in stabilising hemodynamics after major cardiac procedures.

Milrinone may be associated with a range of adverse reactions that clinicians monitor during therapy.

Common Side Effects: - Hypotension: drop in blood pressure, especially with rapid infusion. - Arrhythmias: premature ventricular contractions or tachyarrhythmias. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Flushing: warmth and redness of skin. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: profound blood pressure fall requiring intervention. - Ventricular tachycardia or fibrillation: life‑threatening rhythm disturbances. - Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion. - Thrombocytopenia: notable drop in platelet count. - Hepatic enzyme elevation: increased ALT/AST levels. - Allergic reactions: rash, urticaria, or anaphylaxis.

Milrinone therapy requires careful patient assessment and monitoring.

Cardiovascular monitoring: continuous ECG and blood pressure observation. Electrolyte balance: correct potassium and magnesium before initiation. Renal function: adjust infusion in patients with impaired clearance. Concomitant vasodilators: use cautiously to avoid excessive hypotension. Severe aortic stenosis: contraindicated due to risk of outflow obstruction. Store at ambient temperature: keep in original container, protect from light and moisture.

Milrinone can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid): - Other phosphodiesterase‑3 inhibitors: additive inotropic and vasodilatory effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase plasma concentrations. - Nitrates: risk of severe hypotension.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt inotropic response. - Calcium channel blockers: potential for enhanced vasodilation. - Diuretics: electrolyte shifts may predispose to arrhythmias. - Digoxin: monitor for synergistic effects on cardiac rhythm.